- Home
- QLYS vs TOVX Comparison
QLYS vs TOVX Comparison
Compare QLYS & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | TOVX |
|---|---|---|
| Founded | 1999 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 7.3M |
| IPO Year | 2012 | 2006 |
Fundamental Metrics
Financial Performance| Metric | QLYS | TOVX |
|---|---|---|
| Price | $142.06 | $0.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 1 |
| Target Price | ★ $139.43 | N/A |
| AVG Volume (30 Days) | 396.3K | ★ 2.8M |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.91 | N/A |
| EPS | ★ 5.16 | N/A |
| Revenue | ★ $653,034,000.00 | N/A |
| Revenue This Year | $11.99 | N/A |
| Revenue Next Year | $7.58 | N/A |
| P/E Ratio | $27.71 | ★ N/A |
| Revenue Growth | ★ 10.13 | N/A |
| 52 Week Low | $112.61 | $0.17 |
| 52 Week High | $155.47 | $2.08 |
Technical Indicators
Market Signals| Indicator | QLYS | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 38.79 |
| Support Level | $137.87 | $0.17 |
| Resistance Level | $144.97 | $0.24 |
| Average True Range (ATR) | 4.34 | 0.02 |
| MACD | -1.16 | -0.00 |
| Stochastic Oscillator | 31.30 | 24.56 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.